Evidence-based summary of mechanisms of RAS inhibitors in improving the prognosis of CAD
ACEIs can reduce the incidence of cardiovascular events by various mechanisms, which act on angiotensin-converting enzymes, inhibit angiotensin II synthesis and bradykinin degradation. First, ACEIs can improve endothelial function, increase bradykinin levels and expression and activity of endothelial nitric oxide synthase, decrease the expression of smooth muscle proliferation factor, and improve endothelium-dependent vasodilation; second, ACEIs can inhibit vascular inflammation to delay the progression of atherosclerosis; and, third, these drugs can reduce metalloproteinase activation, thrombosis, improve plaque stability and fibrinolytic activity. In addition, they can antagonize proliferation and delay myocardial remodeling after myocardial infarction (MI) [Langeveld et al. 2005; Ferrario, 2006 ]. ARBs act on angiotensin II receptors (mainly AT1 receptors; valsartan has the most elective AT1/AT2 receptor affinity, 30,000:1) [Siragy, 2002] . ARBs block the function of AT1 receptors leading to an increase in blood pressure, oxidative stress, and water-sodium retention and promote the effect of AT2 receptors of antioxidative stress, antiproliferation, and remodeling [Siragy, 2002] . ARBs are similar to ACEIs in controlling blood pressure, providing a cardioprotective effect, and have fewer adverse reactions [Ma et al. 2010] . Both ACEIs and ARBs improve prognosis in patients with CAD mainly by inhibiting myocardial remodeling, delaying ventricular enlargement, and reducing the incidence of heart failure, thus reducing the rate of hospitalizations, MI, mortality, etc. [Von Lueder and Krum, 2013] .
Chinese and international guidelines recommend that all patients with CAD having comorbidities, including diabetes, heart failure, hypertension, and left ventricular dysfunction after MI should initiate ACEIs early and for a long period of time [Hamm et al. 2011; O'Gara et al. 2013] Alternatively, an ARB can be used if an ACEI is contraindicated in such patients. The main clinical trials showing the protective roles of ACEIs and ARBs in cardiovascular diseases are summarized in Tables 1 and 2.
Evidence-based summary of mechanisms of RAS inhibitors in reducing ISR
The cause and mechanisms of ISR are complex and involve endothelial injury, thrombosis, proliferation of smooth muscle cells, vascular remodeling, inflammatory reaction, and release of various cytokines. ISR can be divided into four stages: (1) platelet aggregation, in which stent implantation results in mechanical endothelial damage and rapidly triggers platelet aggregation and activation; (2) inflammation, in which different types of white cells gather at the lesion location and secrete inflammatory factors within a few days to weeks; (3) proliferation, in which With captopril, the reduction in the risk for death from all causes was 19% (p = 0.019) and that for death from CV causes was 21% (p = 0.014). TRACE [Kober et al. 1995] 6676 patients after MI (partial LVEF fall)
Trandolapril (1 mg/day) versus placebo
Trandolapril reduced the risk of CV mortality in patients with LVSD after MI (RR=0.75; p = 0.001) HOPE [Yusuf et al. 2000] 9297 high-risk patients with CV disease (CV risk factor including diabetes)
Ramipril ( vascular smooth muscle cells (VSMCs) migrate, proliferate, and produce neointima to repair injured vessels; and (4) remodeling, in which neointima rich in cells turn into plaques of rich extracellular matrix [Kraitzer et al. 2008] .
Studies show that RAS is involved in platelet aggregation, thrombosis, and VSMC proliferation [Burnier and Brunner, 2000] . A large number of AT1 receptors are distributed in the VSMCs at restenosis sites, and angiotensin II can promote the proliferation of VSMCs DNA synthesis [Daemen et al. 1991] . The effect of angiotensin-II-mediated AT 2 receptor stimulation include antiproliferation/inhibition of cell growth, cell differentiation, tissue repair, and apoptosis [Burnier and Brunner, 2000 ].
Groenewegen and colleagues showed that angiotensin II can promote angiogenesis in rats after stent implantation [Groenewegen et al. 2008] .
Valsartan was also found to reduce the proliferation of neointima in rats with balloon injury [Li et al. 2014 ]. Ohtani and colleagues showed that valsartan can reduce neointima formation and ISR in macaques after stent implantation [Ohtani et al. 2006 ] . These fundamental studies have shown that ARBs can reduce the occurrence of restenosis. Similar conclusions were drawn from several clinical trials [Peters et al. 2001 [Peters et al. , 2005 Peters, 2008; Yoshikawa et al. 2009 ]. However, the role of ACEIs in reducing the incidence of restenosis is still controversial. Meurice and colleagues showed that treatment with ACEIs significantly increased the incidence of ISR (p = 0.018) in patients with deletion (DD) genotype [Meurice et al. 2001 ]. However, Guneri and colleagues showed that treatment with ACEIs may reduce the incidence of ISR in type 2 diabetic patients with D allele (DD or insertion/deletion [ID]) [Guneri et al. 2005] . Therefore, the role of ACEIs in reducing the incidence of restenosis needs to be studied further. The evidence on the role of ARBs in reducing ISR is summarized in Table 3 . No difference was observed in the rates of cardiovascular mortality and morbidity (primary endpoint); valsartan can reduce the incidence of new-onset diabetes (OR = 0.78; p = 0.034) Val-HeFT [Cohn et al. 2001] 5010 patients with heart failure (NYHA class II-IV) Valsartan (160 mg twice daily) versus placebo Valsartan reduced the risk of composite endpoint of mortality (RR = 0.87; p = 0.009) VALIANT 14,703 patients after MI Valsartan (20 mg/day-160 mg twice daily) versus valsartan (20 mg/day-80 mg twice daily) + captopril (6.25 mg/day-50 mg thrice daily) versus captopril (6.25 mg/day-50 mg thrice daily)
No difference was observed in the mortality rate in high-risk patients after MI (HR [valsartan group versus captopril group]= 1.00; p = 0.98)
OPTIMAAL [Dickstein and Kjekshus, 2002] 5477 high-risk patients after AMI (heart failure, left ventricular dysfunction)
Losartan (50 mg/day) versus captopril (50 mg thrice daily)
The rate of all-cause mortality was higher in the losartan group than that in the captopril group (RR = 1.13); however, this was not statistically significant (p = 0.07) ONTARGET [ONTARGET Investigators et al. 2008] 25,620 patients with cardiovascular disease and diabetes mellitus Telmisartan (80 mg/day) versus ramipril (10) Telmisartan reduced the risk of composite endpoint of death from cardiovascular causes and was noninferior to ramipril (RR = 1.01); the revascularization rate was equivalent to that with ramipril (RR = 1.03) CHARM 7601 patients with LVEF Candesartan (32 mg/day) versus placebo Candesartan reduced the risk of cardiovascular mortality (HR = 0.88; p = 0.012) AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, myocardial infarction; OR, odds ratio; RR, relative risk.
Summary
Moran and colleagues forecasted that the incidence of cardiovascular diseases in China will double from 2010 to 2030 due to ageing and growth of the population and increasing major cardiovascular risk factors will also accelerate this rate of increase [Moran et al. 2010 ]. PCI has been widely used as one of the most crucial therapies of CAD and ISR is a major drawback of PCI. RAS plays a fundamental role in maintaining vascular function and its dysfunction results in cardiovascular disease. RAS inhibitors such as ACEIs and ARBs are used extensively for the treatment of cardiac disease. Likewise, RAS could play a role ARB+statins can reduce the incidences of ISR an d TLR ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndromes; ARB, angiotensin II receptor blocker; ISR, in-stent restenosis; MACE, major adverse cardiovascular events; PTCA, percutaneous transluminal coronary angioplasty; PCI, percutaneous coronary intervention; RASI, renin-angiotensin system inhibitor; TLR, target lesion revascularization; TVR, target vascular revascularization.
in the pathophysiology of ISR. Studies have shown that RAS inhibitors could improve prognosis in patients after MI and reduce ISR. The mechanism relates to improved endothelial function, increased bradykinin levels, reduced expression of VSMC proliferation factors, inhibition of inflammation, reduced thrombosis, etc. This makes RAS inhibitors an appealing approach for the reduction of ISR. However, more research is needed to determine a standardized administration of ACEIs/ARBs after a PCI procedure.
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